CP-640186

CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation[1][2].

Product Specifications

CAS Number

[591778-68-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Acetyl-CoA Carboxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/CP-640186.html

Concentration

10mM

Purity

99.72

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@H]1CN(C2CCN(C(C3=C(C=CC=C4)C4=CC5=C3C=CC=C5)=O)CC2)CCC1)N6CCOCC6

Molecular Formula

C30H35N3O3

Molecular Weight

485.62

Precautions

H302, H315, H319

References & Citations

[1]Harwood HJ Jr, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem. 2003 Sep 26;278 (39) :37099-111.|[2]Yamashita T, et al. Design, synthesis, and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors. Bioorg Med Chem Lett. 2011 Nov 1;21 (21) :6314-8.|[3]Daniel Hess, et al. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One. 2010 Jun 30;5 (6) :e11394.